Drug Type Small molecule drug |
Synonyms CXR 1002, CXR-1002, CXR1002 |
Target |
Action agonists, stimulants |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC8H4F15NO2 |
InChIKeyYOALFLHFSFEMLP-UHFFFAOYSA-N |
CAS Registry3825-26-1 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Phase 1 | - | - | |
| Solid tumor | Phase 1 | United Kingdom | - | |
| Ovarian Cancer | Preclinical | United Kingdom | 15 Apr 2010 | |
| Pancreatic Cancer | Preclinical | United Kingdom | 15 Apr 2010 | |
| Sarcoma | Preclinical | United Kingdom | 15 Apr 2010 |
Phase 1 | 41 | tduqqencgg(uhxkqrgdtg) = ebtahjskzk mglpfnmeiu (kztyfhlxqd ) | - | 20 May 2011 |





